Novanta Inc NOVT
- Employees
- 3,000
- Headquarters
- Bedford, MA
- CEO
- Matthijs Glastra
- Next results
- around Feb 22, 2027
Where each dollar of revenue went, FY2025
Revenue of $980.6M through the costs to a net profit of $53.8M · income statement of the 10-K
NOVT among Technology peers
Six ratios from the latest 10-K. Each corner is the share of 230 peers the company is above, not a score.
What changed
3 new risk paragraphs and 2 accounting facts worth reading about. 10-K filed Feb 23, 2026 against Feb 25, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
11 checks on the latest 10-K. Checks, not verdicts.
2facts worth reading about the other 9 checks found nothing to note
-
Receivables growing faster than revenueReceivables +22.4% ($151.0M to $184.9M) vs revenue +3.3% ($949.2M to $980.6M), +19.1 pts apart
-
Inventory growing faster than revenueInventory +30.2% ($144.6M to $188.3M) vs revenue +3.3% ($949.2M to $980.6M), +26.9 pts apart
-
Cash from operations $64.1M vs net income $53.8M (FY ending Dec 31, 2025)
8 more checks with nothing to note
-
Same auditor in both 10-Ks: Deloitte & Touche LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No longer listed: Motion Solutions Acquisition
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
3 paragraphs in Risk Factors that were not in the 10-K filed Feb 25, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
On June 16, 2025, an amendment to the UK Medical Devices Regulations became applicable, and it strengthened the post-market surveillance requirements for medical devices in Great Britain. In addition, the MHRA launched a consultation from November 14, 2024 to January 5, 2025 on proposals to update the pre-market requirements for medical…
-
Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
In addition, the market price of our common shares may be influenced by the Units. For example, the market price of our common shares could become more volatile and could be depressed by (i) investors’ anticipation of the potential resale in the market of a substantial number of our additional common shares received upon settlement of…
New risk paragraphs, against peers
Latest 10-K of each, Technology companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $860.9M | $881.7M | $949.2M | $980.6M |
| Net income | $74.1M | $72.9M | $64.1M | $53.8M |
| Operating cash flow | $90.8M | $120.1M | $158.5M | $64.1M |
| Free cash flow | $71.1M | $100.1M | $141.3M | $48.4M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$980.6M ▲ 3.3% in FY2025$53.8M ▼ 16.0% in FY2025$48.4M ▼ 65.7% in FY2025
Recent filings
4 filings in the last 30 days · SEC EDGAR
-
Planned saleNov 9, 2026Robert J. Buckley (Chief Financial Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 56,250 shares, runs to Apr 30, 2027
-
Planned saleNov 9, 2026John J. Burke (Chief Accounting Officer) adopted a 10b5-1 trading plan reported in the 10-Q, up to 4,000 shares, runs to Aug 20, 2027
-
8-KNov 9, 2026Quarterly results 8-K item 2.02
-
10-QNov 9, 2026Quarterly report (10-Q) period ended Oct 2, 2026
About the company
Novanta Inc, Bedford, MA · from the 10-K filed Feb 23, 2026
Novanta Inc. and its subsidiaries (collectively referred to as the “Company”, “Novanta”, “we”, “us”, “our”) is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers (“OEMs”) a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine, precision manufacturing, robotics and automation, and advanced surgery with a proven ability to solve complex technical challenges. This enables us to engineer proprietary technology solutions that deliver extreme precision and performance, tailored to our customers' demanding applications.
- Headquarters
- Bedford, MA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 9, 2026
- Incorporated in
- New Brunswick, Canada
Employees, at the top of the page: "As of December 31, 2025, we employed approximately 3,000 people, of which approximately 36% were in the United States, 55% in Europe, and 9% in Asia" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 23, 2026 (open at SEC), compared with the 10-K filed Feb 25, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/NOVT/export.csv") into a cell.